All Type of News
More generics on Tarceva over Iressa facing patent expiration
While blockbuster targeted drugs, Roche’s ‘Tarceva’ and AstraZeneca’s ‘Iressa’ will be expired in patent, there are more pharmaceutical companies which acquired approval on Tarceva generics than the one of Iressa even...
Pfizer Pharmaceuticals Korea divided into ‘Pharmaceutical’ & ‘PFE’Pfizer Pharmaceuticals Korea(CEO Dong-uk Oh) announced change of business and corporate operation plans in terms of the Pfizer headquarters’ reorganization.
The Pfizer Pharmace...
|
Biopharmaceutical companies’ spread of acquisitions on medium & small companies
It seems biopharmaceutical companies will make moves on M&As on medium & small companies.
This is because biopharmaceutical companies which have focused on researches and developments are expanding themselves through...
Domestic companies have no choice but to silently wait until NOACs’ patent expiration
Although domestic pharmaceutical companies have tried to enter the market of novel oral anticoagulant(NOAC) generics, they have kept failed.
NOACs, which were confirmed to be used as a primary therapy with efficacy o...
‘Waiting group’ vs ‘hardliners’ over Lyrica
The market of generics for the painkiller, ‘Lyrica,’ has been fueled. As about 30 products were newly approved only this year, the list of products waiting for Lyrica now consists of more than 100 products.
Unlike th...
Trend of combination therapies for acne, led by multinational companies
Acne is a major disease which patients visit dermatologists for a long term for.
Fortunately, there are various types of acne therapies in the market unlike the past. As long as patients find suitable drugs for thei...
Improvement measures on innovative drugs, biosimilars and insured drug prices
The two amendments on the pricing system for global innovative and biopharmaceutical drugs and the market drug price reduction system, which drew focused interests of the pharmaceutical industry from the beginning of ...
KRPIA, “The government’s promotion measure leans towards domestic new drugs”
The Korean Research-based Pharma Industry Association(President Ok-yeon Kim, KRPIA) expressed discomfort on the fact the value of new drugs was not sufficiently reflected while positively evaluating the government’s a...
MOHW, “It is unlikely increase the number of household drugs to more than 20”
It seems it will be difficult the number of emergency household drugs to exceed more than 20 products at convenient stores.
When it comes to the part of industry’s concern that the number will exceed more than 50 pr...
Roche’s one more attempts on Alzheimer’s disease therapies
In the Alzheimer’s disease therapy market, Roche was known to recently start domestic clinical trials one after another. Since they are clinical trials after experiencing failures on the two drugs for clinical trials ...
